NIS - libdoc.who.int - World Health Organization

WHO monographs on medicinal plants commonly used in the Newly Independent States (NIS)
Contraindications
In patients with biliary obstructions, existing or previous liver disease or
hepatitis, concomitant use of hepatotoxic substances is contraindicated
(80, 85).
Warnings
Use of the crude drug and preparations of Herba Chelidonii should be
restricted to short-term use (1–4 weeks) and long-term use (for more than
4 weeks) is not recommended. Due to the potential for liver toxicity, liver
enzymes should be evaluated prior to and during use (81, 86, 87). Health
professionals should be encouraged to report any suspected adverse reactions
thought to be associated with Herba Chelidonii.
Precautions
General
Use only under professional supervision. In patients with gallstones, the
product should not be used without medical advice (4). The plant is subject
to legal restrictions in some countries (88, 89). The Drug and Medicinal
Product Institute of Germany recommends a maximum daily dose of
2.5 mg total alkaloids, which is lower than the recommended doses prescribed
by other authorities (3, 5, 89).
Drug interactions
No information was found.
Carcinogenesis, mutagenesis, impairment of fertility
No information was found.
Pregnancy
The use of Herba Chelidonii during pregnancy is not recommended (90).
Nursing mothers
The use of Herba Chelidonii while breastfeeding is not recommended (90).
Other precautions
No information was found.
Dosage forms
Crude drug, powdered drug for infusions, tablets containing 4 mg total
alkaloids (56).
84